Benitec Biopharm Financials
This page shows Benitec Biopharm (BNTC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is funding a pre-revenue drug-development model, leaving the company cash-rich even while operations consume $23.6M a year
Cash rose to$97.7M from$50.9M , but that improvement did not come from commercialization or tighter spending. Financing inflows of$70.5M more than covered operating cash burn of-$23.6M , so the stronger liquidity reflects recapitalization while the core operation still behaves like a cash-consuming development program.
The expense mix shifted meaningfully: SG&A reached
The balance sheet is unusually clean for a company at this stage, with
Financial Health Signals
Benitec Biopharm does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Benitec Biopharm passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Benitec Biopharm reported a net loss of $37.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Benitec Biopharm's EBITDA was -$41.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 86.1% from the prior year.
Benitec Biopharm reported -$37.9M in net income in fiscal year 2025. This represents a decrease of 74.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Benitec Biopharm recorded an outflow of $23.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 20.5% from the prior year.
Benitec Biopharm held $97.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Benitec Biopharm's ROE was -39.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.1 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Benitec Biopharm invested $18.3M in research and development in fiscal year 2025. This represents an increase of 17.4% from the prior year.
Benitec Biopharm invested $18K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 89.9% from the prior year.
Not reported for fiscal year 2025.
BNTC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $0-100.0% | $75K+2.7% | $73K+23.7% | $59K-42.2% | $102K-99.2% | $12.2M |
| R&D Expenses | $18.4M | $18.3M+17.4% | $15.6M+22.2% | $12.8M+13.3% | $11.3M+60.6% | $7.0M+133.9% | $3.0M-34.3% | $4.6M |
| SG&A Expenses | $28.2M | $23.4M+235.3% | $7.0M+9.5% | $6.4M-4.0% | $6.6M+2.1% | $6.5M+17.0% | $5.6M+20.7% | $4.6M |
| Operating Income | -$46.6M | -$41.8M-85.7% | -$22.5M-17.9% | -$19.1M-6.9% | -$17.9M-31.3% | -$13.6M-64.2% | -$8.3M-420.6% | $2.6M |
| Net Income | -$41.5M | -$37.9M-74.3% | -$21.8M-11.2% | -$19.6M-7.4% | -$18.2M-31.2% | -$13.9M-67.8% | -$8.3M-417.1% | $2.6M |
| EPS (Diluted) | -$0.93 | -$1.05 | -$1.22 | -$14.12 | -$37.88 | -$3.23 | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BNTC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $99.6M+90.8% | $52.2M+1069.6% | $4.5M-25.3% | $6.0M-72.1% | $21.4M+84.5% | $11.6M-39.8% | $19.2M |
| Current Assets | $98.5M+90.7% | $51.7M+1285.7% | $3.7M-22.6% | $4.8M-76.6% | $20.6M+90.7% | $10.8M-42.4% | $18.8M |
| Cash & Equivalents | $97.7M+92.2% | $50.9M+1953.5% | $2.5M-39.0% | $4.1M-79.5% | $19.8M+101.7% | $9.8M-37.6% | $15.7M |
| Total Liabilities | $2.3M-53.7% | $5.0M+16.4% | $4.3M+37.9% | $3.1M+125.8% | $1.4M+1.5% | $1.3M-48.9% | $2.6M |
| Current Liabilities | $1.8M-63.4% | $4.9M+23.8% | $4.0M+57.1% | $2.5M+85.0% | $1.4M+20.5% | $1.1M-57.0% | $2.6M |
| Total Equity | $97.3M+105.9% | $47.2M+23290.1% | $202K-93.0% | $2.9M-85.6% | $20.0M+95.4% | $10.2M-38.3% | $16.6M |
| Retained Earnings | -$228.2M-19.9% | -$190.3M-13.3% | -$167.9M-13.2% | -$148.3M-14.0% | -$130.1M-11.6% | -$116.6M-7.1% | -$108.9M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BNTC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.8M | -$23.6M-21.6% | -$19.4M-7.7% | -$18.0M-13.3% | -$15.9M-23.9% | -$12.8M-70.3% | -$7.5M-257.3% | $4.8M |
| Capital Expenditures | N/A | $18K-89.9% | $179K+17800.0% | $1K-92.3% | $13K-94.1% | $221K+132.6% | $95K-76.5% | $404K |
| Free Cash Flow | N/A | -$23.6M-20.5% | -$19.6M-8.7% | -$18.0M-13.2% | -$15.9M-21.9% | -$13.1M-71.1% | -$7.6M-274.0% | $4.4M |
| Investing Cash Flow | -$26K | -$18K+89.9% | -$179K-17800.0% | -$1K+92.3% | -$13K+94.1% | -$221K-135.1% | -$94K+76.5% | -$400K |
| Financing Cash Flow | $101.5M | $70.5M+3.6% | $68.0M+324.8% | $16.0M | N/A | $22.5M+1172.4% | $1.8M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BNTC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | -25441.3% | -24457.5% | -23044.1% | -8118.6% | 21.2% |
| Net Margin | N/A | N/A | -26082.7% | -24942.5% | -23528.8% | -8111.8% | 21.4% |
| Return on Equity | -39.0%+7.1pp | -46.0%+9638.1pp | -9684.2%-9052.4pp | -631.8%-562.4pp | -69.4%+11.4pp | -80.8%-96.5pp | 15.7% |
| Return on Assets | -38.1%+3.6pp | -41.7%+396.6pp | -438.2%-133.4pp | -304.8%-239.9pp | -64.9%+6.5pp | -71.4%-85.0pp | 13.6% |
| Current Ratio | 54.67+44.2x | 10.49+9.6x | 0.94-1.0x | 1.90-13.1x | 15.05+5.5x | 9.52+2.4x | 7.10 |
| Debt-to-Equity | 0.02-0.1x | 0.10-21.0x | 21.10+20.0x | 1.07+1.0x | 0.07-0.1x | 0.130.0x | 0.16 |
| FCF Margin | N/A | N/A | -24017.3% | -21797.3% | -22123.7% | -7480.4% | 35.9% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Benitec Biopharm Ranks
Frequently Asked Questions
Is Benitec Biopharm profitable?
No, Benitec Biopharm (BNTC) reported a net income of -$37.9M in fiscal year 2025.
What is Benitec Biopharm's EBITDA?
Benitec Biopharm (BNTC) had EBITDA of -$41.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Benitec Biopharm's return on equity (ROE)?
Benitec Biopharm (BNTC) has a return on equity of -39.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Benitec Biopharm's free cash flow?
Benitec Biopharm (BNTC) recorded an outflow of $23.6M in free cash flow during fiscal year 2025. This represents a -20.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Benitec Biopharm's operating cash flow?
Benitec Biopharm (BNTC) recorded an outflow of $23.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Benitec Biopharm's total assets?
Benitec Biopharm (BNTC) had $99.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Benitec Biopharm's capital expenditures?
Benitec Biopharm (BNTC) invested $18K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Benitec Biopharm spend on research and development?
Benitec Biopharm (BNTC) invested $18.3M in research and development during fiscal year 2025.
What is Benitec Biopharm's current ratio?
Benitec Biopharm (BNTC) had a current ratio of 54.67 as of fiscal year 2025, which is generally considered healthy.
What is Benitec Biopharm's debt-to-equity ratio?
Benitec Biopharm (BNTC) had a debt-to-equity ratio of 0.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Benitec Biopharm's return on assets (ROA)?
Benitec Biopharm (BNTC) had a return on assets of -38.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Benitec Biopharm's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Benitec Biopharm (BNTC) held $97.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.6M over that year. Dividing the one by the other, the reported balance equals about 50 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Benitec Biopharm's Piotroski F-Score?
Benitec Biopharm (BNTC) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Benitec Biopharm's earnings high quality?
Benitec Biopharm (BNTC) reported a net loss of $37.9M while operations used $23.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.